AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Swedish Orphan Biovitrum has agreed to an additional Kineret drug campaign with Amgen.
(From Hugin)
Stockholm, Sweden - March 12, 2009 - Swedish Orphan Biovitrum (STO: BVT) today announced an agreement with Amgen to run an additional Kineret() bulk drug campaign. In addition, Swedish Orphan Biovitrum will pay to buy-out previously agreed future sales milestones for Kineret and Kepivance.
Under the agreement Amgen will run an additional Kineret() campaign at its Boulder facility in Colorado, as well as manufacture drug product at its facility in Puerto Rico. The objective of this additional campaign is to meet an expected increased market demand of Kineret() until Swedish Orphan Biovitrum has transferred manufacturing processes to new contract …
-
- Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in...
-
News wire article from: Europe Intelligence Wire
January 25, 2010
700+ words
-
- Swedish Orphan Biovitrum launches Willfact under its distribution agreement...
-
News wire article from: Europe Intelligence Wire
April 8, 2010
700+ words
-
- Biovitrum AB and Swedish Orphan AB combine to form Swedish Orphan Biovitrum.
-
News wire article from: Chemical Business Newsbase
November 5, 2009
700+ words
-
- Swedish Orphan Biovitrum and Pharming sign Rhucin distribution agreement.
-
News wire article from: Europe Intelligence Wire
April 15, 2010
700+ words
-
- Swedish Orphan Biovitrum has decided to move Kiobrina into phase III...
-
News wire article from: Europe Intelligence Wire
April 21, 2010
700+ words
